MAG-AN is an international scientific consultancy enabling the transition to non-animal, human-relevant biomedical research. Founded by Benjamin Anbiah, CSci, we operate at the intersection of scientific innovation, validation, and regulatory alignment.
We support biotech companies, research organisations, and translational programmes in adopting microphysiological systems (MPS), advanced 3D tissue models, and non-animal testing strategies through a compliance-first approach. Our work focuses on delivering reproducible, regulator-ready, and globally aligned R&D outcomes across the UK, US, and India.
Showcasing our clients’ successful projects
Proposal outlining scope and objectives
Testing phase officially begins
Final reports successfully delivered
We provide comprehensive science research solutions, covering every stage from planning and analysis to reporting and results.

Advanced 3D tissue models that closely replicate human tissue structure and function for accurate research outcomes.

Microphysiological systems that replicate human organ functions for predictive and translational research.

Non-animal testing strategies that provide ethical, reliable, and human-relevant research outcomes.
Related questions help users explore additional information connected to the main topic. They address common concerns, clarify key points, and provide deeper insight for better understanding.
MAG-AN provides scientific and technical consultancy services supporting the development, validation, and translation of advanced cell culture, 3D tissue, and non-animal model technologies. This includes NAM and MPS strategy, regulatory and quality alignment, laboratory setup and operations, and funding and translational support for biotech and life-science organisations.
Strategy discussions and consultations can be booked directly through the website using the “Book Now” option. These sessions are designed to explore scientific, regulatory, and translational needs and to identify appropriate support pathways based on project stage and objectives.
Advanced 3D tissue models are validated using a fit-for-purpose approach that considers biological relevance, functional performance, and reproducibility. Validation may include structural and phenotypic characterisation, functional assays relevant to the intended application, comparative benchmarking, and robustness testing. Validation strategies are tailored to the model type and research question, with alignment to non-animal and translational research expectations.
Founder & Director
Founder of MAG-AN Scientific & Technical Consultancy, Benjamin is a Chartered Scientist with 10+ years of translational research experience in advanced cell culture, 3D tissue engineering, and microphysiological systems. He has created and validated oncology and cardiac tissue models across macro, micro, and chip-based platforms, with a strong focus on non-animal methodologies (NAMs), regulatory alignment, and UK–EU translational pathways.
Chief Technology Officer
Dr. Yuan Tian is a biomedical engineer and scientist with deep expertise in microfluidics and advanced in vitro disease modelling. As CTO, he provides strategic technical guidance on platform development, validation approaches, and translational integration of microphysiological systems within MAG-AN’s UK–EU lab hub and partner ecosystem.
Contact our team today to explore how we can support your research with trusted expertise and proven scientific solutions.